<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850563</url>
  </required_header>
  <id_info>
    <org_study_id>D12129</org_study_id>
    <nct_id>NCT01850563</nct_id>
  </id_info>
  <brief_title>A Proof-of-principle Study of HBO-SRS for Brain Metastases</brief_title>
  <official_title>A Proof-of-principle Study of Hyperbaric Oxygen as a Radiosensitizer Prior to Stereotactic Radiosurgery for Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with brain metastases who are candidates for treatment with stereotactic&#xD;
      radiosurgery (SRS) are potential study participants. SRS delivers high-energy,&#xD;
      precisely-focused radiation to each brain metastasis to shrink the tumor, and is the&#xD;
      standard-of-care for patients with these tumors. Oxygen enhances the damaging effects of&#xD;
      radiation on tumor cells. Hyperbaric oxygen (HBO) therapy increases oxygen levels in all&#xD;
      kinds of tissues, including tumors. The purpose of this trial is to study whether it is&#xD;
      feasible to treat patients with HBO just prior to receiving SRS, given the timing constraints&#xD;
      of treating sequentially with HBO and then SRS. Patients will undergo HBO treatment followed&#xD;
      by the placement of a Gill-Thomas-Cosman head frame then transported ,via stretcher, to&#xD;
      receive SRS. The transfer and placement of the head frame needs to be completed within the&#xD;
      15minute time frame. The trial's secondary objectives are to determine whether it has any&#xD;
      effects on outcomes and quality of life. As part of study participation patients will be&#xD;
      asked to complete quality of life questionnaires as well as mini mental status&#xD;
      questionnaires. These will be done prior to treatment and at follow up appointments&#xD;
      throughout the next 3 years while participating in the study. Patients will be given the&#xD;
      option to participate in the optional bio marker blood draw study which would require&#xD;
      patients to have blood drawn at three time points, pre-treatment, the day after treatment and&#xD;
      at their first follow up visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2013</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">October 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Average Time From HBO Chamber Exit to SRS beam-on</measure>
    <time_frame>Approximately 30 minutes during SRS Treatment Visit</time_frame>
    <description>Time from end of HBO decompression to start of SRS treatment will be measured to determine feasibility. Feasibility is defined as having been achieved if more than 50% of the 20 evaluable patients start SRS treatment within 30 minutes of leaving the HBO tank</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Years</measure>
    <time_frame>5 year from treatment</time_frame>
    <description>Median time to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Years Until Local Recurrence</measure>
    <time_frame>5 year from treatment</time_frame>
    <description>Number of years until recurrence of lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Years Until Local Recurrence Prior to WBRT</measure>
    <time_frame>5 year from treatment</time_frame>
    <description>Number of years until local recurrence of lesion prior to whole brain radiation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing Intercranial Distant Recurrence</measure>
    <time_frame>5 year from treatment</time_frame>
    <description>Number of participants who developed intercranial distant recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Months Between SRS Treatment and Whole Brain Radiation Therapy</measure>
    <time_frame>5 year from treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lesions Exhibiting Radionecrosis</measure>
    <time_frame>5 year from treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Average Score of Quality of Life as Measured by St. Louis University Mental Status Exam (SLUMS) Mental Status Exam (SLUMS)</measure>
    <time_frame>Baseline, 4 to 6 weeks after treatment and then every 3 months for a minimum of 1 year, up to 5 years</time_frame>
    <description>SLUMS is an 11-item screening tool to evaluate cognitive ability in adults. The SLUMS score ranges from 1-30. For patients with a high school education, the normal range score is 27-30. For mild neurocognitive disorder, the score range is 21-26. Dementia range is 1-20. For patients with less than a high school education the normal range score is 25-30. For mild neurocognitive disorder, the score range is 20-24. Dementia range is 1-19.&#xD;
The scores across all time points were averaged to obtain the mean.</description>
  </other_outcome>
  <other_outcome>
    <measure>Average Score of EORTC Global Health Status (QL2)</measure>
    <time_frame>Baseline, 4 to 6 weeks after treatment and then every 3 months for a minimum of 1 year, up to 5 years</time_frame>
    <description>Averages score QL2 determined by responses to aggregate combined results of questionnaires (QLQ C-30 and BN-20).&#xD;
EORTC Quality of Life Questionnaire C-30 (QLQ C-30): 30-item self-report questionnaire rating items on a 4-point scale (1 &quot;not at all&quot; to 4 &quot;very much&quot;) It measures several domains (physical, role, emotional, cognitive, and social functioning, fatigue, pain, nausea and vomiting) and several single items. Scores are averaged for each scale and transformed to 0-100 scale; higher score indicates better QoL on global health status and functional scales and worse QoL on symptom scales and financial difficulty scale.&#xD;
EORTC QLQ BN-20 (BN-20): 4 scales comprised of multiple items and 7 single items. All items are rated on a 4-point Likert-type scale, 1=not at all' to 4=very much, and linearly transformed to a 0-100 scale, higher scores indicating more severe symptoms.&#xD;
The scores across all time points were averaged to obtain the mean.</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence of S100 and NSE (Serum Markers for Tissue Apoptosis and for Neuronal Damage)</measure>
    <time_frame>24-48 hours after the SRS treatment</time_frame>
    <description>Serum markers for tissue apoptosis and for neuronal damage</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>HBO feasibility</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</intervention_name>
    <arm_group_label>HBO feasibility</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Metastatic brain tumor referred to radiation oncology for treatment&#xD;
&#xD;
          -  Size of the presenting metastatic lesion up to 5.0 cm diameter&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Patients must give informed consent indicating they are aware of the investigational&#xD;
             nature of this treatment&#xD;
&#xD;
          -  Karnofsky Performance Status &gt; 70% (Zubrod score 0 to 1)&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 14 days to start of study therapy&#xD;
&#xD;
          -  CBC and CMP within 30 days to start of study therapy&#xD;
&#xD;
          -  Chest imaging (Chest Xray or Chest CT) within past 12 months, that does not show any&#xD;
             contraindication to hyperbaric therapy (if patient has had any thoracic surgery or&#xD;
             other significant event that might have affected the thorax such as trauma,&#xD;
             pneumothorax, chest tube insertion, pleurodesis, or thoracentesis and has not had&#xD;
             imaging since that event, then the imaging should be repeated).&#xD;
&#xD;
          -  Neurosurgery Consult&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Pregnant women or women of childbearing potential without adequate contraception.&#xD;
             Contraception, which can include abstinence, is required since the last menstrual&#xD;
             period until completion of SRS.&#xD;
&#xD;
          -  Evidence of pneumothorax (Untreated pneumothorax risks tension pneumothorax during&#xD;
             ascent in HBO chamber)&#xD;
&#xD;
          -  COPD with C02 retention (Such patients can develop respiratory depression as HBO&#xD;
             reduces their hypoxemic drive)&#xD;
&#xD;
          -  Uncontrolled seizure disorder (Note that patients on adequate antiepileptic&#xD;
             medications may receive HBO)&#xD;
&#xD;
          -  Claustrophobia resistant to medication (Pre-medication with anxiolytics is generally&#xD;
             sufficient for almost all anxious patients undergoing HBO treatment)&#xD;
&#xD;
          -  History of middle ear surgery&#xD;
&#xD;
               -  Failure to equalize pressure in the middle ear can cause displacement of middle&#xD;
                  ear structures with consequent hearing loss&#xD;
&#xD;
               -  To clarify: placement of a tympanostomy tube is not a contraindication to HBO,&#xD;
                  and in fact may improve tolerability of the procedure&#xD;
&#xD;
          -  History of bleomycin administration (HBO can exacerbate interstitial pneumonitis in&#xD;
             such patients)&#xD;
&#xD;
          -  Current cis-platinum chemotherapy, i.e. therapeutic levels in the bloodstream at the&#xD;
             time of HBO therapy. (HBO can increase cytotoxicity of cis-platinum)&#xD;
&#xD;
          -  Uncontrolled high blood pressure (HBO can increase systemic vascular resistance)&#xD;
&#xD;
          -  Unstable angina or myocardial infarction within the previous 3 months (Increased&#xD;
             afterload due to HBO can increase myocardial workload)&#xD;
&#xD;
          -  Cardiac EF â‰¤ 35%&#xD;
&#xD;
               -  Pulmonary edema can arise with HBO in certain patients with severe heart failure&#xD;
&#xD;
               -  In patients with prior history of CHF, subsequent echocardiogram and ECG are&#xD;
                  required to establish EF&gt;35%&#xD;
&#xD;
          -  Treatment with disulfiram (Disulfiram inhibits superoxide dismutase and is not&#xD;
             approved for use concomitantly with hyperbaric oxygen therapy)&#xD;
&#xD;
          -  Active drug/alcohol dependence or abuse&#xD;
&#xD;
          -  Lack of adequate social support structures, e.g. homelessness&#xD;
&#xD;
          -  Tumors with potential confounding results on serum marker studies&#xD;
&#xD;
               -  Small cell (neuroendocrine) carcinomas&#xD;
&#xD;
               -  Carcinoid tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Hartford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <results_first_submitted>April 27, 2021</results_first_submitted>
  <results_first_submitted_qc>July 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2021</results_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Alan Hartford</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Demonstrate coordination of HBO with SRS treatments is feasible.</keyword>
  <keyword>Demonstrate outcomes for patients treated with combination of HBO and SRS are non-inferior .</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT01850563/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HBO feasibility subjects were recruited from potential candidates for stereotactic radiosurgery (SRS) treatment at DHMC for brain metastases. Such patients are referred to radiation oncology by practitioners at DHMC and by physicians at outlying hospitals.&#xD;
Historic Controls: Retrospective review of previous patients utilizing SRS in the treatment of brain metastases. The control population was selected based on matching variables.</recruitment_details>
      <pre_assignment_details>Adverse events were not collected for historic controls.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HBO Feasibility</title>
          <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
        </group>
        <group group_id="P2">
          <title>Historic Controls</title>
          <description>Retrospective review of previous patients utilizing SRS in the treatment of brain metastases. The matching variables (histology, lesion size, resection status, and calculated GPA) will be used to identify this control population.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>HBO Treatment Completed</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not eligible</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HBO Feasibility</title>
          <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO. Demographic information (Race, gender, ethnicity, and age) were collected for only the participants who were prospectively enrolled and provided informed consent.</description>
        </group>
        <group group_id="B2">
          <title>Historic Controls</title>
          <description>Retrospective review of previous patients utilizing SRS in the treatment of brain metastases. The matching variables (histology, lesion size, resection status, and calculated GPA) will be used to identify this control population.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Average Time From HBO Chamber Exit to SRS beam-on</title>
        <description>Time from end of HBO decompression to start of SRS treatment will be measured to determine feasibility. Feasibility is defined as having been achieved if more than 50% of the 20 evaluable patients start SRS treatment within 30 minutes of leaving the HBO tank</description>
        <time_frame>Approximately 30 minutes during SRS Treatment Visit</time_frame>
        <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HBO Feasibility</title>
            <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
          </group>
        </group_list>
        <measure>
          <title>The Average Time From HBO Chamber Exit to SRS beam-on</title>
          <description>Time from end of HBO decompression to start of SRS treatment will be measured to determine feasibility. Feasibility is defined as having been achieved if more than 50% of the 20 evaluable patients start SRS treatment within 30 minutes of leaving the HBO tank</description>
          <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="5" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Years</title>
        <description>Median time to death</description>
        <time_frame>5 year from treatment</time_frame>
        <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HBO Feasibility</title>
            <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
          </group>
          <group group_id="O2">
            <title>Historic Controls</title>
            <description>Retrospective review of previous patients utilizing SRS in the treatment of brain metastases. The matching variables (histology, lesion size, resection status, and calculated GPA) will be used to identify this control population.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Years</title>
          <description>Median time to death</description>
          <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" lower_limit="0.96" upper_limit="2.35"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.57" upper_limit="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Years Until Local Recurrence</title>
        <description>Number of years until recurrence of lesion</description>
        <time_frame>5 year from treatment</time_frame>
        <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HBO Feasibility</title>
            <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
          </group>
          <group group_id="O2">
            <title>Historic Controls</title>
            <description>Retrospective review of previous patients utilizing SRS in the treatment of brain metastases. The matching variables (histology, lesion size, resection status, and calculated GPA) will be used to identify this control population.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Years Until Local Recurrence</title>
          <description>Number of years until recurrence of lesion</description>
          <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="1.45" upper_limit="NA">Insufficient data (only one observed occurrence)</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0.70" upper_limit="NA">Insufficient data (only one observed occurrence)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Years Until Local Recurrence Prior to WBRT</title>
        <description>Number of years until local recurrence of lesion prior to whole brain radiation therapy</description>
        <time_frame>5 year from treatment</time_frame>
        <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HBO Feasibility</title>
            <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
          </group>
          <group group_id="O2">
            <title>Historic Controls</title>
            <description>Retrospective review of previous patients utilizing SRS in the treatment of brain metastases. The matching variables (histology, lesion size, resection status, and calculated GPA) will be used to identify this control population.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Years Until Local Recurrence Prior to WBRT</title>
          <description>Number of years until local recurrence of lesion prior to whole brain radiation therapy</description>
          <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="1.45" upper_limit="NA">Insufficient data (only one observed occurrence)</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0.70" upper_limit="NA">Insufficient data (only one observed occurrence)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing Intercranial Distant Recurrence</title>
        <description>Number of participants who developed intercranial distant recurrence</description>
        <time_frame>5 year from treatment</time_frame>
        <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HBO Feasibility</title>
            <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
          </group>
          <group group_id="O2">
            <title>Historic Controls</title>
            <description>Retrospective review of previous patients utilizing SRS in the treatment of brain metastases. The matching variables (histology, lesion size, resection status, and calculated GPA) will be used to identify this control population.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing Intercranial Distant Recurrence</title>
          <description>Number of participants who developed intercranial distant recurrence</description>
          <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Kaplan-Meier</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Months Between SRS Treatment and Whole Brain Radiation Therapy</title>
        <time_frame>5 year from treatment</time_frame>
        <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis. 17 participants in the HBO group, and 14 historical controls did not receive whole brain radiation therapy</population>
        <group_list>
          <group group_id="O1">
            <title>HBO Feasibility</title>
            <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
          </group>
          <group group_id="O2">
            <title>Historic Controls</title>
            <description>Retrospective review of previous patients utilizing SRS in the treatment of brain metastases. The matching variables (histology, lesion size, resection status, and calculated GPA) will be used to identify this control population.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Months Between SRS Treatment and Whole Brain Radiation Therapy</title>
          <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis. 17 participants in the HBO group, and 14 historical controls did not receive whole brain radiation therapy</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="1.5" upper_limit="23.3"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.7" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lesions Exhibiting Radionecrosis</title>
        <time_frame>5 year from treatment</time_frame>
        <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HBO Feasibility</title>
            <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
          </group>
          <group group_id="O2">
            <title>Historic Controls</title>
            <description>Retrospective review of previous patients utilizing SRS in the treatment of brain metastases. The matching variables (histology, lesion size, resection status, and calculated GPA) will be used to identify this control population.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lesions Exhibiting Radionecrosis</title>
          <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis.</population>
          <units>Lesions exhibiting radionecrosis</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Kaplan-Meier</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Score of Quality of Life as Measured by St. Louis University Mental Status Exam (SLUMS) Mental Status Exam (SLUMS)</title>
        <description>SLUMS is an 11-item screening tool to evaluate cognitive ability in adults. The SLUMS score ranges from 1-30. For patients with a high school education, the normal range score is 27-30. For mild neurocognitive disorder, the score range is 21-26. Dementia range is 1-20. For patients with less than a high school education the normal range score is 25-30. For mild neurocognitive disorder, the score range is 20-24. Dementia range is 1-19.&#xD;
The scores across all time points were averaged to obtain the mean.</description>
        <time_frame>Baseline, 4 to 6 weeks after treatment and then every 3 months for a minimum of 1 year, up to 5 years</time_frame>
        <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis. This information was not available for historical controls.</population>
        <group_list>
          <group group_id="O1">
            <title>HBO Feasibility</title>
            <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
          </group>
        </group_list>
        <measure>
          <title>Average Score of Quality of Life as Measured by St. Louis University Mental Status Exam (SLUMS) Mental Status Exam (SLUMS)</title>
          <description>SLUMS is an 11-item screening tool to evaluate cognitive ability in adults. The SLUMS score ranges from 1-30. For patients with a high school education, the normal range score is 27-30. For mild neurocognitive disorder, the score range is 21-26. Dementia range is 1-20. For patients with less than a high school education the normal range score is 25-30. For mild neurocognitive disorder, the score range is 20-24. Dementia range is 1-19.&#xD;
The scores across all time points were averaged to obtain the mean.</description>
          <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis. This information was not available for historical controls.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Score of EORTC Global Health Status (QL2)</title>
        <description>Averages score QL2 determined by responses to aggregate combined results of questionnaires (QLQ C-30 and BN-20).&#xD;
EORTC Quality of Life Questionnaire C-30 (QLQ C-30): 30-item self-report questionnaire rating items on a 4-point scale (1 &quot;not at all&quot; to 4 &quot;very much&quot;) It measures several domains (physical, role, emotional, cognitive, and social functioning, fatigue, pain, nausea and vomiting) and several single items. Scores are averaged for each scale and transformed to 0-100 scale; higher score indicates better QoL on global health status and functional scales and worse QoL on symptom scales and financial difficulty scale.&#xD;
EORTC QLQ BN-20 (BN-20): 4 scales comprised of multiple items and 7 single items. All items are rated on a 4-point Likert-type scale, 1=not at all' to 4=very much, and linearly transformed to a 0-100 scale, higher scores indicating more severe symptoms.&#xD;
The scores across all time points were averaged to obtain the mean.</description>
        <time_frame>Baseline, 4 to 6 weeks after treatment and then every 3 months for a minimum of 1 year, up to 5 years</time_frame>
        <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis. This information was not available for historical controls.</population>
        <group_list>
          <group group_id="O1">
            <title>HBO Feasibility</title>
            <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO. Demographic information (Race, gender, ethnicity, and age) were collected for only the participants who were prospectively enrolled and provided informed consent. Demographic data was not collected for historic controls.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Score of EORTC Global Health Status (QL2)</title>
          <description>Averages score QL2 determined by responses to aggregate combined results of questionnaires (QLQ C-30 and BN-20).&#xD;
EORTC Quality of Life Questionnaire C-30 (QLQ C-30): 30-item self-report questionnaire rating items on a 4-point scale (1 &quot;not at all&quot; to 4 &quot;very much&quot;) It measures several domains (physical, role, emotional, cognitive, and social functioning, fatigue, pain, nausea and vomiting) and several single items. Scores are averaged for each scale and transformed to 0-100 scale; higher score indicates better QoL on global health status and functional scales and worse QoL on symptom scales and financial difficulty scale.&#xD;
EORTC QLQ BN-20 (BN-20): 4 scales comprised of multiple items and 7 single items. All items are rated on a 4-point Likert-type scale, 1=not at all' to 4=very much, and linearly transformed to a 0-100 scale, higher scores indicating more severe symptoms.&#xD;
The scores across all time points were averaged to obtain the mean.</description>
          <population>Three (3) participants were screen failures, and did not receive study treatment, and not included in the analysis. This information was not available for historical controls.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Presence of S100 and NSE (Serum Markers for Tissue Apoptosis and for Neuronal Damage)</title>
        <description>Serum markers for tissue apoptosis and for neuronal damage</description>
        <time_frame>24-48 hours after the SRS treatment</time_frame>
        <population>Sample donations where optional for the study participants. Insufficient samples were obtained and therefore, samples were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>HBO Feasibility</title>
            <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of S100 and NSE (Serum Markers for Tissue Apoptosis and for Neuronal Damage)</title>
          <description>Serum markers for tissue apoptosis and for neuronal damage</description>
          <population>Sample donations where optional for the study participants. Insufficient samples were obtained and therefore, samples were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) for the HBO Feasibility arm will be collected during the period from the initiation of the study procedures until the date of documented death, withdrawal of consent, or the end of the study, whichever occurs first. Collection could span approximately 5 years. Adverse events were not collected for the historic controls.</time_frame>
      <desc>Symptomatic treatment toxicity: AEs potentially related to intracranial SRS and/or HBO treatments Radiographic evidence for radionecrosis/treatment effects in normal tissue identified by diagnostic radiologist of follow-up MRI imaging. Incidence of WBRT, Incidence of repeat SRS to the index site and a distant site. Local and distant disease recurrence at the treatment site identified by diagnostic radiologist of follow-up MRI imaging. AEs were not collected for historic controls.</desc>
      <group_list>
        <group group_id="E1">
          <title>HBO Feasibility</title>
          <description>Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO</description>
        </group>
        <group group_id="E2">
          <title>Historic Controls</title>
          <description>Retrospective review of previous patients utilizing SRS in the treatment of brain metastases. The matching variables (histology, lesion size, resection status, and calculated GPA) will be used to identify this control population.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Intercranial hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Facial muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan Hartford, MD, PhD, FACR, Professor of Medicine (RadOnc) Director, Radiation Oncology</name_or_title>
      <organization>Dartmouth-Hitchcock Medical Center</organization>
      <phone>603-650-6600</phone>
      <email>Alan.C.Hartford@Hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

